Improvement of the human intestinal flora by ingestion of the probiotic strain Lactobacillus johnsoniiLa1 (original) (raw)

Modulation of the fecal microbiota by the intake of a Lactobacillus johnsonii La1-containing product in human volunteers

Fems Microbiology Letters, 2005

Lactobacillus johnsonii La1 (La1) is a probiotic strain capable of stimulating the immune system of the host and interfering with gastrointestinal pathogens. This study evaluates how the ingestion of different amounts of La1 influences the main bacterial populations of the fecal microbiota. Eight asymptomatic volunteers participated in the study. After a basal period, they ingested daily 100 mL of a product containing 10 8 CFU mL À1 of La1 during the first week, 200 mL during the second week and 500 mL during the third week. Fecal samples were obtained at the end of each period and subsequently during 7 weeks. Lactobacilli were determined by culture on MRS agar and La1 colonies were confirmed by ERIC-PCR. The main populations of fecal bacteria were identified by FISH and flow cytometry. At baseline, 37.7% of the total fluorescent bacteria were Eubacterium rectale, 18.3% Fusobacterium prausnitzii, 13.2% Bacteroides, 8.6% Atopobium, 2.30%, Clostridium histolyticum, 2.05% Bifidobacterium and 0.95% Lactobacillus. Fecal excretion of La1 increased during the intake period and decreased during the post-ingestion period, so that no La1 was observed in the stools of the volunteers seven weeks after the intake product has been finished. La1 intake increased the populations of C. histolyticum (p = 0.049), Lactobacillus (p = 0.056) and Bifidobacterium (p = 0.067), and decreased those of F. prausnitzii (p = 0.005) while it did not affect Bacteroides, E. rectale and Atopobium populations. These bacterial populations returned to their baseline levels during the post-ingestion period. The regular intake of a La1-containing product beneficially affects the homeostasis of the human fecal microbiota, probably contributing to the health-promoting effects of this probiotic. (M. Gotteland). www.fems-microbiology.org FEMS Microbiology Letters 248 (2005) 249-256

A Randomised Controlled Trial of a Probiotic Lactobacillus Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity

Microbial Ecology in Health & Disease, 2002

In severa l intestinal disease states, altered micro ora, impaired gut barrier and:or intestinal in ammation offer a rationale for the effective therapeut ic use of probiotic microorganisms. However , for most candidat e probiotic organisms there is a lack of evidence detailing their characterisation and effects on host ora and immunity. We have previously reported the isolation and characterisation, from surgically resected segment s of the huma n gastrointestinal tract (GIT), of potential probiotic lactic acid bacteria (LAB). We have also described subsequen t animal experimen ts that evaluated the establishment , persistence and localisation of speci c probiotic Lactobacillus strains within the murine intestinal tract, in addition to their ability to in uence the developmen t of murine in ammatory disorders. In these studies, transit and surviva l of Lactobacillus salivarius U CC118 at the ileum was demonstrat ed using enteral tube sampling of six healthy volunteer s following consumption of a single dose (150 ml) of fermented milk-born e probiotic (10 8 colony forming units per ml (CF U :ml)). Subsequently, we performed a randomised controlled trial of 80 volunteer s fed strain UCC118 (10 8 CF U:day for 21 d), using two oral delivery vehicles (fresh milk, n ¾ 20 vs. fermented milk, n ¾ 20; controls, n ¾ 20 for each). Throughout this feeding period , and for up to 100 days following cessation of feeding, the number s of total culturable lactobacilli and of the administered Lactobacillus U CC118 present in faeces were monitored. F ive subjects (5:40; fresh milk, four; fermented milk, one) were still excretin g the probiotic lactobacilli 21 days post-cessatio n of feeding, while one subject (fermented milk) was still colonised up to 100 days after feeding. Consumpt ion of fermented milk-born e UCC118 cells resulted in signi cantly increased levels of faecal-borne enterococci and lactobacilli. N umber s of bi dobacteria, coliforms and bacteroides were not signi cantly altered. In addition, changes in salivary IgA levels against U CC118 cells and increased granulocyt e phagocytic activity were observed following consumption of the fermented milk-borne probiotic. In summary, Lactobacillus UCC118 was found to effectively transit (and persist within) the human intestinal tract, to modify the faeca l ora and to engage the immune system.

Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults

International Journal of Food Microbiology, 2006

Modifications in gastrointestinal parameters, intestinal colonization and tolerance are some of the main goals claimed for probiotics. However, although healthy people are the common target for these new functional food products, the number of clinical trials analysing the effects of probiotics in gastrointestinal parameters of healthy subjects is very scarce. A randomized, double blind, placebo-controlled human clinical trial involving 30 healthy adults was performed to investigate the effect of a fermented product containing two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, on several blood and fecal parameters, most of them related to the host intestinal function. The volunteers were randomly distributed into two groups, one receiving a standard yogurt and the other a similar dairy fermented product in which the Lactobacillus delbreuckii subsp. bulgaricus yogurt strain had been replaced by a combination of the probiotic strains L. gasseri CECT5714 and L. coryniformis CECT5711. The volunteers that received the probiotic strains reported no adverse effects and the strains could be isolated from their feces at a relatively high level. In fact, the concentration of fecal lactic acid bacteria significantly increased in the probiotic group. Additionally, the oral administration of the probiotic strains led to an improvement of parameters such as the production of short chain fatty acids, the fecal moisture and the frequency and volume of the stools. As a result, the volunteers assigned to the probiotic group perceived a clear improvement in their intestinal habits. The study revealed that probiotics may exert a positive effect on healthy adults. D

Probiotic potential of lactobacillus strains in human infections

Probiotics means "for life". Probiotics are naturally occurring beneficial organisms that aid in digestion and inhibit disease-causing bacteria in the intestine. Due to the beneficial impact of microorganism used as Probiotics; during the last decades progressive attention has been focused on biological and molecular characterization and improvement of such microbes during the last decades. Probiotics in the strictest sense, refers to lactic acid producing bacteria Most data accumulated so far have related that lactic acid bacteria are major organisms, which that when given orally will pass through the strong acid of the stomach and the low surface tension of bile and colonize in the intestine, which is their normal habitat. Lactic acid bacteria mainly include Lactobacilli and Bifidobacteria. Various studies have indicated that lactobacillus species may have a positive influence on the intestinal flora of human, alleviate lactose intolerance, have hypocholesterolemic effect, stimulate immunity and have anti-colon cancer effects, Crohn's disease and candidiasis infections. Interest in the field of probiotics has bloomed in recent years and considering the above impressive list of potential health-promoting benefits, it is not surprising that there continues to be considerable interest in the use of probiotics as biotherapeutic tool to improve the diseased conditions of humans although much remains to be elucidated.

Lactobacillus fermentum improved intestinal bacteria flora by reducing Clostridium perfringens

e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 2011

Background & aim: Supplementation with probiotic Bifidobacteria or Lactobacilli or the combination of both, has been shown to maintain a healthy balance of bacterial flora in the intestinal lumen. A placebocontrolled, crossover, self-comparing clinical study evaluated the probiotic effects of Lactobacillus fermentum P.C.C. (ProBioPCC) on gastrointestinal bacterial flora. Methods: This 8-week trial comprised an initial lead-in week with no study intervention, a 3-week treatment phase (taking ProBio, 1 capsule/day), a 1-week washout phase, a 3-week control phase (taking placebo, 1 capsule/day), followed by a final week of washout. Thirty healthy adults (age: 25e43 years) having no gastrointestinal diseases were recruited into the study. Stool samples were collected once at each experimental week, and cultured for counting colonies of total anaerobic bacteria, Lactobacillus spp., Bifidobacterium spp., and Clostridium perfringens. Results: We found significantly increased colony counts of Lactobacillus spp. In stool samples after the treatment phase (p < 0.05). Colony counts of probiotic Bifidobacterium spp. were significantly increased with the study intervention (p < 0.05), while those of harmful C. perfringens were reduced (p < 0.05). Ratios of Bifidobacterium spp. to total anaerobic bacteria and to C. perfringes were increased significantly (p < 0.05). The bacteria colony counts and ratios returned toward baselines during and after the placebo control phase. In order to confirm the increase of intestinal probiotics was due to oral administration of ProBioPCC, we further demonstrated that L. fermentum P.C.C. strain was resistant against simulated gastric acid and bile in vitro. Conclusions: Our data indicate that ProBioPCC is effective in decreasing C. perfringens and increasing ratio of Bifidobacterium spp. to total anaerobic bacteria in healthy humans.

Salutary attributes of probiotic human gut lactobacilli for gut health

Letters in Applied Microbiology

Lactobacilli are GRAS organisms and are important members of gut microbiota. They have been strongly recommended as probiotics because of many benefits provided by them to overall human health. Human gut lactobacilli with salutary properties can provide additional advantages. Limosilactobacillus fermentumL1 MW600457, L. fermentumL3 MW600480, L. fermentumL4 MW600464, L. fermentumL5 MW600493, L. fermentumL6 MW600495, L. fermentumL7 MW600496, L. fermentumL8 MW485761, Lactiplantibacillus plantarumL9 MW485746, and Ligilactobacillus salivariusL10 MW600498 with in vitro probiotic properties were explored for salutogenic characteristics. Salutary properties like β-galactosidase activity, anthelminthic property assay, anti-inflammatory assay, antidiabetic study, cholesterol assimilation assay, and biofilm assay were performed. All the isolates were positive for β-galactosidase activity. The anthelminthic property with minimum paralysis time and death time between 16–25 min was shown by L.fer...

Intestinal Lactobacillus in health and disease, a driver or just along for the ride?

Current Opinion in Biotechnology, 2018

Metagenomics and related methods have led to significant advances in our understanding of the human microbiome. Members of the genus Lactobacillus, although best understood for essential roles in food fermentations and applications as probiotics, have also come to the fore in a number of untargeted gut microbiome studies in humans and animals. Even though Lactobacillus is only a minor member of the human colonic microbiota, the proportions of those bacteria are frequently either positively or negatively correlated with human disease and chronic conditions. Recent findings on Lactobacillus species in human and animal microbiome research, together with the increased knowledge on probiotic and other ingested lactobacilli, have resulted in new perspectives on the importance of this genus to human health.